Dr. Reddy’s is recalling five lots of Javygtor and one lot of generic sapropterin dihydrochloride because discoloration could lead to decreased potency. Sapropterin is used to treat an inherited metabolic disorder.
Dr. Reddy's Laboratories is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg due to powder discoloration in some packets. This could lead to decreased potency. The issue was discovered because of customer complaints and from accelerated stability test.
Sapropterin Dihydrochloride is used to treat adult and pediatric patients one month of age and older with the metabolic disorder hyperphenylalaninemia (HPA) that is the result of tetrahydrobiopterin-responsive Phenylketonuria (PKU). It is indicated to reduce the level of phenylalanine (Phe) in the blood.
Hyperphenylalaninemia is an abnormal increase in the amino acid phenylalanine in the blood. High concentrations of phenylalanine can lead to Phenylketonuria, a condition where there is decreased activity of a liver enzyme called phenylalanine hydroxylase. Untreated, the condition can lead to microcephaly, delayed or absent speech, seizures, eczema, and behavioral issues.
Lowered potency of Sapropterin Dihydrochloride could result in elevated phenylalaninemia levels in patients. Chronically elevated Phe levels in infants and children can cause permanent neurologic deficits.
The recall affects five lots of the branded product Javygtor and one lot of the generic product sapropterin. The products are packaged in individual packets with 30 per carton. NDC and lot numbers of the affected products can be found here.
Javygtor was developed by Cycle Pharmaceuticals, which partnered with Dr. Reddy’s for distribution. Javygtor was launched in October 2022.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More